Alzamend Neuro announced on May 19, 2025, the enrollment of the first patient in its first Phase II clinical study of AL001. This study is being conducted in healthy human subjects at Massachusetts General Hospital.
The trial aims to evaluate AL001's potential to deliver lithium more effectively to the brain while mitigating systemic side effects compared to conventional lithium therapies. This is a crucial step in its clinical development.
Topline data from this study is anticipated by the end of 2025. The enrollment of the first patient signifies active progress in the clinical program for AL001, which targets Alzheimer’s, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.